 |
|
Maximum: 1 CME cr.,
1 AutoAttendance cr.
Sign in to view your progression
|
Activity Title: Chikungunya: Forecasting, Risk Mapping and Clinical Trials
Release Date: March 28, 2022
Estimated Time to Complete Activity: 70 minutes
Statement of Need:
Chikungunya is a mosquito-transmitted alphavirus. Since its emergence in Africa, the global distribution has been rapidly expanding, the disease has spread to most continents. The spread to new areas is possible due to the travel of infected persons and the presence of mosquitoes in these new areas that can spread the disease. The spread is more in tropical and sub-tropical countries. Several data-driven empirical approaches and spatiotemporal forecasting have been used to forecast chikungunya spread in places like the Americas. Some of these forecasting methods have been used to predict infected cases and locations based on machine learning. Although there is currently no specific treatment and vaccine in use, there are several vaccine candidates in different stages of clinical trials that have shown promising results.
Faculty:
Dr. Assaf Anyamba
R&D Staff Member and Group Lead
Remote Sensing, Geographic Data Science Section in the Geospatial Science and Human Security Division at Oak Ridge National Laboratory
Dr. Lin Chen
Associate Professor of Medicine
Institution Mount Auburn Hospital
Cambridge MA
Technical Requirements
This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox and Safari browsers. For interactive content, a broadband connection is required. For CME/CE activities featuring audio you need a sound card and speakers.
Our activities may require JavaScript to be enabled on your computer. If you are having difficulty viewing pop-up windows, click here for instructions on enabling JavaScript.
Contact Information
If you have questions about this CME activity, please contact The International Society for Infectious Diseases at info@isid.org.
For technical support issues, please contact Multilearning at support@multilearning.com
Upon completion of this module, participants should be able to:
- Discuss basic facts about Chikungunya and it's expanding global distribution
- Discuss data-driven empirical approaches and spatiotemporal forecasting that are being used to forecast chikungunya spread in places like the Americas.
- Understand that there is currently no specific treatment or vaccine in use
- Discuss the vaccine candidates that are currently in different stages of clinical trials which have shown promising results.
The target audience for this module is physicians, nurses, public health officials, researchers, immunization officers, and other health professionals.
Del Valle, S., McMahon, B., Asher, J. et al. Summary results of the 2014-2015 DARPA Chikungunya challenge. BMC Infect Dis 18, 245 (2018). https://doi.org/10.1186/s12879-018-3124-7
Braira Wahid, Amjad Ali, Shazia Rafique, Muhammad Idrees. Global expansion of chikungunya virus: mapping the 64-year history. International Journal of Infectious Diseases, 2017.58:69-76 https://doi.org/10.1016/j.ijid.2017.03.006.
Chen GL, Coates EE, Plummer SH, et al. Effect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial. JAMA. 2020;323(14):1369–1377. doi:10.1001/jama.2020.2477
DeFilippis VR. Chikungunya Virus Vaccines: Platforms, Progress, and Challenges. Curr Top Microbiol Immunol. 2022; 435:81-106. doi: 10.1007/82_2019_175. PMID: 31338593.
Disclosure Policy
In accordance with the EACCME Standards for Commercial Support, the International Society for Infectious Diseases (ISID) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. ISID resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all our educational programs. Furthermore, ISID seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. ISID is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of commercial interest.
Activity Staff Disclosures:
The planners, reviewers, editors, staff, or other members at the International Society for Infectious Diseases who control content have no relevant financial relationships to disclose.
ISID Knowledge Exchange and E-Learning Platform Organizing Committee members are listed here, along with Committee members’ disclosure forms.
Faculty Disclosures:
Dr. Assaf Anyamba has no actual or potential conflict of interest in relation to this program.
Dr. Lin Chen has no actual or potential conflict of interest in relation to this program.
Disclosure of Unlabeled Use
The International Society for Infectious Diseases requires CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration-approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. ISID does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The International Society for Infectious Diseases presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The International Society for Infectious Diseases, and the former commercial supporter assume no liability for the information herein.
Copyright Information
Copyright © 2022 by the International Society for Infectious Diseases. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein), without the International Society for Infectious Diseases' prior written permission.
Privacy Policy
The International Society for Infectious Diseases protects the privacy of personal and other information regarding participants and educational collaborators. The International Society for Infectious Diseases will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the EACCME.
The International Society for Infectious Diseases maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
Additional information regarding the International Society for Infectious Diseases Privacy Policy and ISID’s Knowledge Exchange and E-Learning Platform Privacy Policy can be viewed at https://isid.org/privacy-policy/ and https://exchange.isid.org/isid/legal/terms-and-conditions.
|
ACCREDITED ACTIVITY
Chikungunya: Forecasting, Risk Mapping and Clinical Trials
|
|
